Raf/MEK/ERK Signaling Pathway Is Involved in the Inhibition of Glioma Cell Proliferation and Invasion in the Ketogenic Microenvironment

Abstract

Objective

A high-fat, low-carbohydrate ketogenic diet has been used to treat malignant glioma, in which the Raf/MEK/ERK signaling pathway is overactivated. However, whether the Raf/MEK/ERK signaling pathway is involved in the therapeutic effect of ketone bodies remains unknown. In this study, we investigated the effects of a major ketone body, 3-hydroxybutyric acid (3-HBA), on the proliferation and metastasis of malignant glioblastoma cells and the underlying mechanism.

Methods

Two human malignant glioblastoma cell lines (U87 and U251) were treated with different concentrations of 3-HBA with or without the Raf inhibitor PAF C-16 for 24 h. Cell proliferation, cell cycle, cell invasion, and phospholipase D1 (PLD1) activity were determined. Protein and gene expression levels of Raf/MEK/ERK signaling pathway members were examined.

Results

3-HBA significantly decreased cell proliferation, invasion, and intracellular PLD1 activity in both U87 and U251 glioblastoma cell lines. 3-HBA treatment significantly increased the proportion of cells in the G1 phase and decreased the proportion of cells in S phase in U87 cells. In the U251 line, the proportion of treated cells in S phase was increased and proportion of cells in G2 was decreased. 3-HBA treatment also significantly decreased the protein expression levels of Raf, MEK, p-MEK, ERK, p-ERK, and PLD1 while increasing p53 expression; an effect that was similar to treatment with the Raf inhibitor. Co-treatment of 3-HBA with the Raf inhibitor further enhanced the effects of the 3-HBA in both cell lines.

Conclusion

We confirmed that a ketogenic microenvironment can inhibit glioma cell proliferation and invasion by downregulating the expression of PLD1 through the Raf/MEK/ERK signaling pathway.

Keywords

glioma / ketogenic microenvironment / Raf/MEK/ERK

References

[1] Delgado-MartínB, MedinaM. Advances in the knowledge of the molecular biology of glioblastoma and its impact in patient diagnosis, stratification, and treatment. Adv Sci, 2020, 7(9): 1902971

[2] BazylianskaV, KalpageHA, WanJ, et al.. Lysine 53 acetylation of cytochrome c in prostate cancer: Warburg metabolism and evasion of apoptosis. Cells, 2021, 10(4): 802

[3] ChenX, QianY, WuS. The Warburg effect: evolving interpretations of an established concept. Free Radic Biol Med, 2015, 79: 253-263

[4] SchiliroC, FiresteinBL. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells, 2021, 10(5): 1056

[5] PoteetE, ChoudhuryGR, WintersA, et al.. Reversing the warburg effect as a treatment for glioblastoma. J Biol Chem, 2013, 288(13): 9153-9164

[6] SeyfriedTN, FloresR, PoffAM, et al.. Metabolic therapy: a new paradigm for managing malignant brain cancer. Cancer Lett, 2015, 356: 289-300 2 Pt A

[7] SteinhardtMJ, KrummenastFC, RosenwaldA, et al.. R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement. J Cancer Res Clin Oncol, 2022, 148(1): 205-214

[8] Vander HeidenMG, CantleyLC, ThompsonCB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 2009, 324(5930): 1029-1033

[9] LeeYG, ParkDH, ChaeYC. Role of Mitochondrial Stress Response in Cancer Progression. Cells, 2022, 11(5): 771

[10] ZhangY, ZhangT, YangW, et al.. Beneficial diets and pancreatic cancer: Molecular mechanisms and clinical practice. Front Oncol, 2021, 11: 630972

[11] OrangAV, PetersenJ, McKinnonRA, et al.. Micromanaging aerobic respiration and glycolysis in cancer cells. Mol Metab, 2019, 23: 98-126

[12] MiyauchiT, UchidaY, KadonoK, et al.. Up-regulation of FOXO1 and reduced inflammation by β-hydroxybutyric acid are essential diet restriction benefits against liver injury. Proc Natl Acad Sci U S A, 2019, 116(27): 13533-13542

[13] VenishettyVK, SamalaR, KomuravelliR, et al.. β-Hydroxybutyric acid grafted solid lipid nanoparticles: a novel strategy to improve drug delivery to brain. Nanomedicine, 2013, 9(3): 388-397

[14] BrennanCW, VerhaakRG, McKennaA, et al.. The somatic genomic landscape of glioblastoma. Cell, 2013, 155(2): 462-477

[15] DegirmenciU, WangM, HuJ. Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. Cells, 2020, 9(1): 198

[16] LoHW. Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets, 2010, 10(8): 840-848

[17] ChenY, ZhengY, FosterDA. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene, 2003, 22(25): 3937-3942

[18] FosterDA, XuL. Phospholipase D in cell proliferation and cancer. Mol Cancer Res, 2003, 1(11): 789-800

[19] de KokJB, RoelofsRW, GiesendorfBA, et al.. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest, 2005, 85(1): 154-159

[20] NagumoY, KandoriS, TanumaK, et al.. PLD1 promotes tumor invasion by regulation of MMP-13 expression via NF-κB signaling in bladder cancer. Cancer Lett, 2021, 511: 15-25

[21] KrisherRL, PratherRS. A role for the Warburg effect in preimplantation embryo development: metabolic modification to support rapid cell proliferation. Mol Reprod Dev, 2012, 79(5): 311-320

[22] YaoB, LiY, ChenT, et al.. Hypoxia-induced cofilin 1 promotes hepatocellular carcinoma progression by regulating the PLD1/AKT pathway. Clin Transl Med, 2021, 11(3): e366

[23] KangDW, HwangWC, NohYN, et al.. Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma. J Cell Physiol, 2021, 236(1): 549-560

[24] BowlingFZ, SalazarCM, BellJA, et al.. Crystal structure of human PLD1 provides insight into activation by PI(4,5)P(2) and RhoA. Nat Chem Biol, 2020, 16(4): 400-407

[25] BjuneMS, LindquistC, Hallvardsdotter StafsnesM, et al.. Plasma 3-hydroxyisobutyrate (3-HIB) and methylmalonic acid (MMA) are markers of hepatic mitochondrial fatty acid oxidation in male Wistar rats. Biochim Biophys Acta Mol Cell Biol Lipids, 2021, 1866(4): 158887

[26] ChappellWH, CandidoS, AbramsSL, et al.. Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. Aging (Albany NY), 2020, 12(11): 10194-10210

[27] YuX, HuangM, YangG. Long non-coding RNA BANCR promotes proliferation, invasion and migration in esophageal squamous cell carcinoma cells via the Raf/MEK/ERK signaling pathway. Mol Med Rep, 2021, 23(6): 465

[28] WuQ, YuanX, LiB, et al.. Salvianolic acid alleviated blood-brain barrier permeability in spontaneously hypertensive rats by inhibiting apoptosis in pericytes via p53 and the Ras/Raf/MEK/ERK pathway. Drug Des Devel Ther, 2020, 14: 1523-1534

[29] LiuK, LiF, SunQ, et al.. p53 β-hydroxybutyrylation attenuates p53 activity. Cell Death Dis, 2019, 10(3): 243

[30] PanY, NussinovR. Lysine120 interactions with p53 response elements can allosterically direct p53 organization. PLoS Comput Biol, 2010, 6(8): e1000878

[31] JoergerAC, AngHC, FershtAR. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A, 2006, 103(41): 15056-15061

[32] SunS, ChenH, SunL, et al.. Hotspot mutant p53-R273H inhibits KLF6 expression to promote cell migration and tumor metastasis. Cell Death Dis, 2020, 11(7): 595